Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center Study to Evaluate the Effectiveness and Safety of SOTYKTU® (Deucravacitinib) in Combination With Enstilar® for Moderate to Severe Plaque Psoriasis

NCT06329258 is registered in ClinicalTrials.gov with Psoriasis Treatment Center of Central New Jersey as lead sponsor.

NCT NCT06329258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06329258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center Study to Evaluate the Effectiveness and Safety of SOTYKTU® (Deucravacitinib) in Combination With Enstilar® for Moderate to Severe Plaque Psoriasis
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Phase
Phase 4
Overall status
Completed
Start date
December 6, 2022
Completion date
November 13, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis